Richard Sykes (microbiologist) facts for kids

Sir Richard Sykes, born on August 7, 1942, is a famous British scientist who studies tiny living things called microbes (a microbiologist). He leads important groups like the Royal Institution, the UK Stem Cell Foundation, and is the head of Brunel University. Since 2021, he has been in charge of the UK's Vaccine Taskforce. This means he helps make sure everyone gets their COVID-19 vaccines and that new vaccines are developed.

After finishing his studies in microbiology, Sir Richard started working at a company called Glaxo in 1972. There, he helped create a medicine called ceftazidime, which fights infections. Later, he moved to the Squibb Institute in the United States. He developed aztreonam, the first "monobactam" antibiotic. He even came up with the name "monobactam" in 1981 for this new type of medicine.

Sir Richard also played a big role in combining major drug companies. He helped merge Glaxo with Wellcome in 1995 to form Glaxo-Wellcome. Then, in 2000, he oversaw the merger of Glaxo Wellcome with SmithKline Beecham, creating GlaxoSmithKline, one of the world's largest pharmaceutical companies. He was the chairman of this new company until 2001.

His other important jobs include being the head of Imperial College London from 2001 to 2008. He also chaired NHS London and Imperial College Healthcare.

Early Life and Education

Richard Sykes was born on August 7, 1942, in Huddersfield, England. He went to Royds Hall Grammar school. Before finishing school, he worked as a technician in a lab that studies diseases.

He later went to Paddington Technical College and Chelsea College. Then, he studied at Queen Elizabeth College, where he earned a top degree in microbiology. In 1972, he received his PhD from the University of Bristol. His research was about how bacteria can become resistant to medicines. In 1973, he helped create a way to classify these resistance mechanisms.

Developing New Medicines

GlaxoSmithKline Headquarters in Brentford, London

In 1972, Sir Richard became the head of the Antibiotic Resistance Unit at Glaxo. Here, he helped create ceftazidime, an antibiotic used to treat serious infections.

In 1977, he moved to the Squibb Institute for Medical Research in the United States. He led research into a new type of antibiotic. He found a substance called SQ26.180 from a special kind of bacteria. By changing it, he created aztreonam. This was the first "monobactam" antibiotic. He named this new group of antibiotics in 1981. Aztreonam could treat infections like gonorrhoea and was approved for use in hospitals.

From 1983 to 1986, he was a vice-president at Squibb, focusing on infectious diseases. He returned to Glaxo in 1987. He was known for encouraging his teams, even when projects faced difficulties. In 1993, he received a higher science degree (DSc).

In 1994, while at Glaxo, he helped start the Jenner Institute. This institute focuses on researching and developing vaccines.

Leading Big Companies

In 1995, Sir Richard oversaw the merger of Glaxo with Wellcome. This created Glaxo-Wellcome. In 1997, he became the chairman of Glaxo-Wellcome. In 2000, he led another big merger, combining Glaxo Wellcome with SmithKline Beecham to form GlaxoSmithKline. This merger led to many new medicines being sold. Sir Richard believed that understanding the human genome (our genetic code) would change the medicine industry.

Important Roles and Leadership

Sir Richard was chosen as a Fellow of the Royal Society (FRS) in 1997. This is a very high honor for scientists. He also became a trustee of the Natural History Museum, London in 1994.

Imperial College

In 2001, he became the head (rector) of Imperial College London, a famous university. He stayed in this role until 2008. At Imperial, he was involved in discussions about university fees and the quality of science education.

UK Stem Cell Foundation

Sir Richard leads the UK Stem Cell Foundation, which started in 2005. This foundation supports research into stem cells, which are special cells that can develop into many different cell types.

Other Key Positions

He was a trustee of the Royal Botanic Gardens, Kew from 2003 to 2005. He also held leadership roles at companies like Eurasian Natural Resources Corporation and Lonza AG. In 2008, he became the chairman of NHS London, which manages health services in London. He resigned in 2010 due to disagreements about health care changes.

In 2010, he became the chairman of the Royal Institution. In 2013, he was appointed the head (Chancellor) of Brunel University.

Vaccine Taskforce

In 2020, Sir Richard led a review of the UK's Vaccine Taskforce. On June 14, 2021, he was appointed the chairman of this taskforce. In this role, he is in charge of making sure the UK's COVID-19 vaccination program runs smoothly. This includes planning for booster shots and encouraging new vaccine discoveries in the UK.

Awards and Honours

Sir Richard Sykes was made a knight in 1994. This means he can use "Sir" before his name.

He has received special degrees (honorary degrees) from many universities. These include Birmingham, Brunel, Edinburgh, and Leeds. In 1998, he became a Fellow of the Academy of Medical Sciences.

In 2009, he received the Garrod Medal from the British Society for Antimicrobial Chemotherapy. He gave a speech called "The evolution of antimicrobial resistance: a Darwinian perspective." This speech was about how germs become resistant to medicines over time.

Images for kids

• 

  GlaxoSmithKline Headquarters in Brentford, London